It has been suggested that the use of toceranib phosphate, in combination with chemotherapy, may be effective in treating canine metastatic OSA with high PDGFR, VEGFR2 and c-Kit expression [42,43]. The gene discussed is KDR; the disease is obstructive sleep apnea syndrome.